Improving Asthma and COPD Control Through Improving Inhaled Treatment Adherence

Share Article

Nexus6 and Clement Clarke International announce a collaboration aimed at improving the use of inhaled medications.

Nexus6 and Clement Clarke International (CCI) today announced a collaboration aimed at improving the use of inhaled medications. The aim of inhaled medication in asthma and COPD is to enable the patient to maintain control of these conditions, but all too frequently control is not achieved despite widespread availability of effective medications. Some estimates suggest that more than half of patients are inadequately controlled and the consequential costs of poor control exceed $15 billion per year in asthma alone.

Nexus6 is a provider of solutions that monitor and increase patient adherence to prescribed therapies. These solutions include data logging, communications and reminder technologies for use by patients, healthcare professionals and clinical researchers. Nexus6 technology is presently being used in clinical research and disease management. The visibility of actual dosing and improved adherence to therapy is helping patients to achieve disease control.

CCI are the manufacturers of the Mini-Wright peak flow meter that is used throughout the world as a tool for monitoring asthma and adjusting management programmes accordingly. CCI with its range of respiratory products has extensive experience in collaborating with academics and pharmaceutical companies to provide monitoring equipment for respiratory and drug development studies.

Under the terms of the Agreement announced today, CCI will market and distribute Nexus6’s Smartinhaler products in Europe.
Commenting for Nexus6, Founder and COO Garth Sutherland noted “Nexus6 is excited to have CCI represent Nexus6’s Smartinhaler platform in Europe. We are also very excited about the prospect of combining CCI’s expertise in Spirometry with Nexus6’s Smartinhaler platform to provide new applications for our customers.”

For CCI, Mark Sanders, Managing Director, said, “Gaining control in diseases such as asthma is about using medications correctly and to the schedule prescribed, CCI have a number of initiatives in place and in development to help pharmaceutical companies, healthcare professionals and patients get the most from inhaled medications. This collaboration is central to the direction we are headed, and we look forward immensely to working together with Nexus6.”

About Clement Clarke
Clement Clarke International Limited have been developing and manufacturing respiratory devices for over 50 years. CCI was the first company to produce the peak flow meter, which today plays a key role in monitoring asthma. Millions of asthma patients have benefitted from having a Mini-Wright peak flow meter. Additionally CCI manufacturers an inspiratory flow meter, In-Check, used to help healthcare professionals assess and teach inhaler use.

About Nexus6
Nexus6 Limited is a privately owned developer and manufacturer of solutions to monitor and increase patient adherence to prescribed therapies, leading to improved disease management and reduced healthcare costs.
Nexus6 SmartinhalerTM devices monitor and report patients' medication usage to their healthcare partners, and are used in pharmaceutical clinical trials and disease management applications for COPD, asthma and other respiratory diseases.

For Nexus6:
Garth Sutherland, Chief Operating Officer
NZ: +64 307 2771
US: (937) 274 2111 ext 104

For Clement Clarke International:
UK: +44 1279 414969


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Garth Sutherland
Nexus6 Limited
937 274 2111 ext. 104
Email >
Visit website